From the 2026 budget audit
Rural pharmacies need access — but this subsidy treats a symptom, not the cause.
1.05 billion forints props up pharmacies with low dispensing volumes, while the regulations that prevent alternative rural medicine supply go untouched.
About 263 Ft per taxpayer per year — 1.05 billion Ft total — subsidising pharmacy owners in low-demand locations rather than removing the restrictions that prevent better rural access.
What you see — and what you don't
The seen: pharmacy owners receiving a subsidy that keeps their outlets open. The unseen: the rural residents who could be served by a wider variety of dispensing models — mail-order, mobile dispensing, nurse-prescriber access — if the ownership and location restrictions that make low-turnover pharmacies the only option were removed.
Objection
"Without this subsidy, rural communities lose their only local pharmacy."
Answer
The subsidy treats the symptom of an over-regulated market, not the cause. Hungarian pharmacy ownership and location rules restrict how rural medicine supply can be organised. Remove those restrictions and new delivery models — dispensing by trained nurses, consolidated rural pharmacies covering larger catchments, remote dispensing — become possible. Three years to phase the subsidy out pairs with deregulation that addresses rural access directly.
Share if you think rural healthcare access needs deregulation, not a subsidy.
The analyst's verdict
Support for low-turnover pharmacies
Rationale
This subsidises pharmacies with low dispensing volume — typically rural pharmacies. The line concentrates benefit on a defined group of pharmacy owners while spreading the cost across all taxpayers, and it props up an outlet network at a scale the underlying demand does not support. A genuine rural-access concern is better met by removing the regulatory restrictions on pharmacy ownership, location and dispensing that limit how rural medicine supply can be organised — the subsidy treats a symptom of an over-regulated market.
Transition mechanism
A three-year phase-out at 350 millió Ft per year protects pharmacy owners who invested on the expectation of the subsidy and pairs the wind-down with the deregulation that addresses rural access directly.
Affected groups
Rural pharmacy owners who currently receive the subsidy and must adjust business models; rural populations whose medicine access will be sustained by regulatory deregulation rather than subsidy.
Free Society Institute
Support independent analysis
Our research is free, open, and unsponsored. If you find it valuable, help us keep it that way.